(0.16%) 5 477.90 points
(0.04%) 39 128 points
(0.49%) 17 805 points
(0.06%) $80.88
(-5.04%) $2.62
(-0.90%) $2 309.80
(-0.36%) $28.77
(2.90%) $1 015.00
(0.35%) $0.936
(0.64%) $10.67
(0.51%) $0.792
(0.87%) $88.25
-9.21% $ 1.725
Live Chart Being Loaded With Signals
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally...
Stats | |
---|---|
Volumen de hoy | 129 682 |
Volumen promedio | 113 731 |
Capitalización de mercado | 2.55M |
EPS | $-9.11 ( Q4 | 2023-12-31 ) |
Próxima fecha de ganancias | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0295 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.699 (28.77%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-02 | Kayne Richard A | Buy | 23 398 | Common Stock |
2023-11-01 | Kayne Richard A | Buy | 100 000 | Common Stock |
2023-10-31 | Kayne Richard A | Buy | 130 509 | Common Stock |
2023-10-31 | Kayne Richard A | Buy | 12 345 | Common Stock |
2023-10-31 | Kayne Richard A | Buy | 11 987 | Common Stock |
INSIDER POWER |
---|
56.31 |
Last 89 transactions |
Buy: 3 414 696 | Sell: 449 818 |
Volumen Correlación
Eiger BioPharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Eiger BioPharmaceuticals Correlación - Moneda/Commodity
Eiger BioPharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $15.77M |
Beneficio Bruto: | $15.75M (99.85 %) |
EPS: | $-50.78 |
FY | 2023 |
Ingresos: | $15.77M |
Beneficio Bruto: | $15.75M (99.85 %) |
EPS: | $-50.78 |
FY | 2022 |
Ingresos: | $13.48M |
Beneficio Bruto: | $11.65M (86.38 %) |
EPS: | $-69.74 |
FY | 2021 |
Ingresos: | $12.14M |
Beneficio Bruto: | $11.40M (93.86 %) |
EPS: | $-1.000 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico